Clinical Trials in Tennessee

Showing 12101-12120 of 17,345 trials

Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

NCT01832883

The purpose of this project is to compare the performance of the Pediatric Vision Scanner (PVS) with the Gold Standard Examination to determine the effectiveness of the PVS at detecting amblyopia and strabismus.

AmblyopiaStrabismus

Rebiscan, Inc.78 participantsStarted Dec 2010

Nashville, Tennessee, United States

COMPLETEDPhase 1/229 miles

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

NCT01958970

This is a pilot study to assess the safety, pharmacokinetics and effectiveness of PINTA 745 or placebo in treating protein energy wasting (PEW) in patients receiving maintenance hemodialysis (MHD).

End Stage Renal DiseaseKidney DiseaseProtein Energy Wasting

Pinta Biotherapeutics51 participantsStarted Jan 2014

Lakewood, Colorado, United States • Orlando, Florida, United States • Minneapolis, Minnesota, United States +3 more locations

COMPLETEDPhase 129 miles

A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01875705

This is an open-label, multicenter, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0994 in patients with locally advanced or metastatic solid tumors. Patients will be enrolled in one of two stages: a dose-escalation stage (Stage I) or the subsequent expansion stage (Stage II). Stage I will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0994 administered daily. Stage II will gather additional data on safety, tolerability, and pharmacokinetics of the recommended dose of GDC-0994 determined in Stage I.

Solid Tumor

Genentech, Inc.40 participantsStarted Jun 2013

New Haven, Connecticut, United States • Detroit, Michigan, United States • Nashville, Tennessee, United States +1 more locations

Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Find Trials by Condition in Tennessee

Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site

A Study in Participants With Type 2 Diabetes Mellitus

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens:Bioequivalence of PVP Formulations

A Study for Patients With Type 1 Diabetes

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites

Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus